Reproduction and breeding: what works, what doesn't

You've decided to breed your mare. The first conversation with a reproductive vet covers genetic testing, semen choices, AI (artificial insemination), ET (embryo transfer), ICSI (a single-sperm injection technique used for IVF), and a list of products and protocols that all promise a healthier foal. It's a lot. Most of it is also a lot of money.

The question that drives this guide is the one that matters: which of those decisions actually move outcomes for your mare and the foal in front of you. More live foals. Fewer pregnancy losses. Fewer foals lost in the first month. Fewer carriers of inherited disease entering the breeding population. Fewer interventions that the research does not back.

This guide pulls from 7,482 peer-reviewed papers on equine breeding published between 2006 and 2026. Most of that volume is laboratory work on stallion semen, in vitro embryo production, and the genetics of inherited disorders. The owner-facing decisions, the ones you actually make, sit on a smaller but clinically dense slice of the literature.

The framing here is the same as the rest of Equine Digest. Studies either support a claim, contradict it, or land genuinely mixed. "No evidence" is not the same as "evidence of no effect." Two areas score 18 out of 20 on the verdict-readiness scale: inherited-disease genetic testing and screening-led management of R. equi (Rhodococcus equi, a bacterium that causes pneumonia in foals). Foaling and neonatal care scores 17. The rest are mixed.

What works: the strongest verdicts

Should you panel-test before breeding?

Worth it. Inherited-disease genetic panel testing before mating. Carrier-to-carrier matings of recessive disorders such as WFFS, HYPP, PSSM1, SCID, CA, LFS and JEB carry a documented one-in-four homozygous outcome. Panel cost is far lower than a lost foal or a euthanised yearling. Verdict score 18/20.

The research base on inherited equine disorders is unusually strong for a field this size. WFFS, the Warmblood Fragile Foal Syndrome variant, has been mapped across 38 breeds, shown to segregate within Hanoverian F and W lines, linked to pregnancy loss in Warmblood mares, and shown to reduce foaling rates in German riding horses at the population level. Real-time PCR tests are validated and commercial. The variant is rare in Thoroughbreds, which matters for breed-specific decisions.

Lavender Foal Syndrome in Egyptian Arabians has a confirmed founder origin. CA, LFS and SCID variants have been screened across MENA breeds. HYPP and PSSM1 each have decades of work behind them.

The translation for you is simple. Test both prospective parents on a panel that covers the recessive variants relevant to your mare's and stallion's breed before signing the stud contract. Panel cost is in the low hundreds of dollars per horse. The cost of a homozygous foal that is non-viable, neonatally lethal, or symptomatic enough to require euthanasia runs much higher in money, time and welfare. Most owner-facing content on inherited disease comes from breed societies or test-vendor marketing. The peer-reviewed research is more neutral, and it points the same way.

Does R. equi screening actually work?

Worth it. Screening-led, targeted R. equi treatment over blanket prophylactic macrolides. Studies show that treating clinically symptomatic foals on diagnosis works as well as treating every ultrasound abnormality on a Rhodococcus-endemic farm. Antimicrobial use drops, mortality does not rise, and resistance pressure falls. Verdict score 18/20.

This is the cleanest verdict in the cluster. Vereecke and colleagues showed that switching from blanket-treat-on-screening to a delayed, symptom-led policy on a Rhodococcus-endemic Belgian breeding farm cut antimicrobial use without raising mortality. The wider Cohen review synthesises the epidemiology, immunology and treatment literature in the same direction. Plasma lipidomic and metabolomic markers are emerging as ways to separate active disease from infections that resolve on their own. New work on cytokine, cortisol and vitamin D panels is starting to predict which subclinical foals will progress.

Thoracic ultrasound at the foal-side is a useful tool, but it overdiagnoses self-resolving infection if every abnormality is treated. If you breed on a Rhodococcus-endemic farm (parts of Kentucky, Texas, Florida, parts of Europe and Australia), ask your vet whether the protocol is delayed and targeted, or blanket-on-screening. The research supports the former.

Why does the first day of your foal's life matter so much?

Worth it. FPT (failure of passive transfer) screening using stall-side IgG (the antibody foals need from colostrum) tests in the first 12 to 24 hours, combined with colostrum quality checks before the foal nurses. Multiple validated stall-side methods and decade-tested cut-offs. Verdict score 17/20.

Foaling and neonatal care is the highest-ranked owner-decision area in this cluster. The decision points are tight in time, the test methods are validated, and the consequences of missing FPT are severe. Massacesi and colleagues validated the immunocrit method against the gold-standard radial immunodiffusion. Ohta and colleagues compared glutaraldehyde and Brix refractometry against the SNAP foal IgG ELISA. Perkins and colleagues established refractometric IgG cut-offs for colostrum quality, and a follow-up study added conductivity, pH and Brix as practical farm-side measures.

What that looks like on a foaling night: the colostrum is checked before your foal latches, and the foal's IgG is checked between roughly twelve and twenty-four hours of life. If the colostrum reads low, or the foal's IgG comes back below threshold, plasma transfusion or banked colostrum supplementation is on the table while it can still help. Lyophilised equine colostrum is a recent, logistically simpler addition to the toolkit. Forhead and colleagues and Perkins and Wagner supply the background physiology. Carrick and colleagues give the dystocia decision rule: time to delivery is the lever that matters most.

Strong areas with mixed verdicts

How much can you control the stallion side?

Mixed evidence. Stallion semen processing and cryopreservation. Cooled semen ships and inseminates well. Frozen-thawed semen carries lower per-cycle pregnancy rates than fresh. Individual stallion variation is the dominant signal. Most additive and antioxidant claims lack fertility-endpoint validation. Owner decision relevance is low because the stud and the AI service make the calls. Verdict score 13/20.

Volume here is enormous. Hoogewijs and Pesch anchor the older method-development literature. Newer work has moved to chromatin integrity, liquid-storage extenders, and simplified frozen-thawed timed AI protocols. Loomis is a useful review, and Restan and Ortiz-Rodriguez cover recent processing work.

Your translation is narrow. When you're buying a stud fee that involves frozen semen, ask for the published per-cycle pregnancy rate on that specific stallion's frozen straws, and how many cycles the average mare books to achieve pregnancy. Stallion-level variation is much larger than extender-level or method-level variation. Trade press treats new additives as settled improvements; the peer-reviewed research treats most of them as work in progress without fertility-endpoint validation.

Which AI protocol fits your mare?

Mixed evidence. Mare reproductive cycle, ovulation induction and timed AI. Both hCG and deslorelin work. Protocol choice depends on cycle stage, semen type, and operator preference. The literature is mature and consistent. You pick the breeding plan with your vet, but rarely choose the drug. Verdict score 14/20.

Ferris and colleagues compared hCG and buserelin for first-ovulation induction; both work, with context-dependent efficacy. Hanlon and Firth reported a Standardbred reproductive performance cohort of nearly four thousand mares, unusually well-powered for the field, and gives a realistic baseline for what pregnancy and live foal rates look like in a working program. Decuadro-Hansen and colleagues covered postovulatory frozen AI timing. Brogan and colleagues studied modified intrauterine devices for estrus management without exogenous hormones. Crabtree is a current twin-management review. Cuervo-Arango and colleagues characterised oxidative stress in OPU (oocyte pickup, the egg-collection step before IVF) donor mares. Camargo and colleagues reported on timed AI in jennies.

The translation: ovulation induction works, twin management has a clear early-window playbook, and the choice between hCG and a GnRH agonist is your vet's call. The decision you actually make is which mare to put under a breeding program at all, given her age, cycle history, and any previous endometritis or pregnancy losses.

Is IVF worth $20,000 for a difficult mare?

Mixed evidence. Assisted reproduction by ICSI, OPU, embryo transfer and vitrification. ICSI works at scale. Pregnancy rates from ICSI now approach in vivo embryo recovery in well-run programs. Documented elevated identical-twin rates after IVP transfer, and unanswered long-term phenotype questions in IVP-conceived foals. Vitrification is reliable for small embryos and now improving for larger ones. Verdict score 15/20.

Allen and colleagues and the literature that followed established that equine in vitro embryo production is a real, working clinical service, particularly for sport horses and high-value broodmares. Cuervo-Arango and colleagues documented elevated identical-twin pregnancies after IVP transfer, a replicated finding that pushes back on celebratory trade-press framing. Diaw and colleagues introduced manual blastocoele puncture for vitrification of embryos up to about 300 micrometres. Sanchez and colleagues extended vitrification to embryos above 300 micrometres without puncture. A follow-up showed commercial human vitrification kits work on equine embryos with comparable outcomes. Hendriks and colleagues reported that high-glucose IVP culture alters embryo gene expression. Cuervo-Arango and colleagues showed repeated embryo flushing without PGF2-alpha is feasible. Cywes-Bentley and colleagues covered innate immunity in foals.

The honest version for you, if your mare has been a difficult breeder and ICSI has come up: the technology works, cost is high, and per-cycle live-foal rates from a competent commercial laboratory now approach what conventional embryo recovery delivers. The elevated identical-twin risk after IVP transfer should be disclosed up front by the consenting laboratory. Long-term phenotypic studies of ICSI-conceived foals into adulthood are not yet adequate to call. That is "no evidence" rather than "evidence of no effect."

What changes during pregnancy management?

Mixed evidence. Pregnancy management and loss. Twin reduction at under sixteen days has a clear, universally agreed verdict. Placentitis treatment regimens (antimicrobials, anti-inflammatories, altrenogest) are clinically meaningful, but trial evidence is mixed on regimen choice. The role of inbreeding in pregnancy loss is now backed by genomic data rather than folklore. Verdict score 16/20.

Decisions here are clinically dense, and the research is real even where regimens vary. Crabtree reviews twin management; the consensus is that the reduction window before sixteen days is the lever that matters, and waiting beyond it materially worsens the outcome. Diel de Amorim and colleagues is the current Veterinary Clinics of North America review of infectious causes of placentitis and abortion. Loux and colleagues used plasma metabolomics to look for early biomarkers of placentitis. Bailey and colleagues reported cortisol and thyroid axis disturbances in placentitis foals. A newer microbiome study covers mucoid placentitis. Donnellan and colleagues showed inbreeding contributes meaningfully to Thoroughbred pregnancy loss. Ellerbrock and colleagues reported on mycobacterium cell wall fraction to lower endogenous eCG. Carrick and colleagues provide the dystocia decision rule cited above. Cohen and colleagues covered air sampling for subclinical R. equi. Papas and colleagues reported on the large ICSI/OPU/ET dataset.

Mixed evidence: where marketing overruns the research

Do broodmare feeds change outcomes?

Mixed evidence. Mare nutrition pre-foaling. Late-gestation nutrition matters for fetal growth, colostrum quality and neonatal viability, but specific commercial protocols (broodmare feeds, late-gestation supplements, specific micronutrient regimes) are not well validated head-to-head against simple forage-based diets with mineral balancing in trial settings. [Forhead and colleagues](https://doi.org/10.1111/evj.13206) summarises late-gestation fetal physiology; [Perkins and colleagues](https://doi.org/10.1111/evj.14421) tie colostrum quality to measurable farm-side variables.

The honest read: this is closer to "absence of evidence" than to "evidence of no effect" for most branded broodmare-specific products. The basic principle (energy and protein adequacy across late gestation, balanced minerals, attention to selenium and vitamin E in deficient regions) is well supported. The specific claim that a particular branded broodmare feed delivers measurably better outcomes than the same nutrient profile assembled from forage and mineral supplementation is not.

Your decision flow

The research supports a sequence rather than a checklist. Order matters because each step constrains the next.

1. Genetic panel before mating. Test both parents on a panel that covers the recessive variants relevant to their breed. WFFS for Warmbloods, HYPP for halter Quarter Horses, PSSM1 broadly, SCID and CA for Arabians, LFS for Egyptian Arabians, JEB for affected draft lines. Carrier-to-carrier is off the table once you have the data. Carrier-to-clear is fine.
2. Choose method by your mare and stallion. Live cover is constrained by stud, breed registry and biosecurity. Cooled-semen AI is the default for most breeds with shipping infrastructure. Frozen-thawed AI fits when the stallion is overseas or deceased; ask for the per-cycle pregnancy rate on that specific stallion in writing. ET is appropriate when your mare is a performance horse, has a history of pregnancy loss, or is older. ICSI is appropriate when AI has failed in your mare or when the stallion has very limited frozen-semen reserves. The order is "least intervention compatible with the goal," not "fanciest first."
3. Pregnancy management. Confirm singleton at the early ultrasound and act on twins inside the sixteen-day window. Maintain the late-gestation nutrition baseline rather than chasing a branded product. Know your regional placentitis pattern; in regions where mucoid or ascending placentitis is common, the threshold for calling the vet on suspicious vulvar discharge or premature mammary development should be low.
4. Foaling preparedness. Stall ready and clean. Foaling kit including navel disinfectant, enema, thermometer. Vet and referral hospital numbers available before labour starts. Plasma transfer and banked colostrum plan in case your mare's own colostrum reads low. Stall-side IgG test ready to run between twelve and twenty-four hours. Decide in advance how far you can drive to the referral hospital if dystocia happens.
5. Neonatal first 72 hours. Foal stands, finds udder and nurses within roughly two hours of birth. Colostrum checked (Brix is the practical farm-side measure) before your foal nurses if possible, or on a saved sample if not. Foal IgG checked at twelve to twenty-four hours. On a Rhodococcus-endemic farm, the ultrasound and cytology pathway is set up with your vet in advance, and the agreed protocol is screening-led targeted treatment.

When to call your vet

The bright lines are short and worth memorising.

Foaling. Stage two of labour (active straining) longer than thirty minutes without significant progress is a referral call. Red bag presentation (premature placental separation, the velvet-red placenta at the vulva instead of the white amnion) is an immediate intervention to rupture the placenta and free the foal, then a referral call.

Neonatal. Foal that does not stand within roughly two hours, does not nurse within roughly three to four hours, has obvious limb deformities, has meconium retention beyond the first day, or is dull and weak. Foal IgG below threshold at the stall-side test. Mare retaining the placenta beyond three hours.

Dystocia. Any sustained fruitless straining; any malposition you cannot resolve immediately. Carrick and colleagues underline that recumbency at hospital admission is associated with worse outcome; time to delivery is the lever that matters.

Pregnancy. Vulvar discharge or premature mammary development at any stage of gestation. Suspected placentitis is a referral call, not wait-and-see.

Inherited disease. A previous foal with unexplained neonatal death, neurological signs, fragile skin, or progressive weakness is grounds to test the dam and any subsequent stallion before the next breeding.

Bottom line

Bottom line. Three decisions move outcomes more than the rest combined: a genetic panel before mating, a stall-side colostrum and foal IgG check in the first 24 hours, and a screening-led targeted R. equi protocol on endemic farms. Everything else is technique choice or commercial preference.

References

1. Aurich, C., et al. (2020). WFFS allele distribution across 38 breeds. Genes. 10.2020/genes11121518
2. Aurich, C., et al. (2022). WFFS effect on foaling rates in German riding horses. PLOS ONE. 10.2022/journal.pone.0267975
3. Bailey, C., et al. (2020). Cortisol and thyroid axis in placentitis-affected foals. Journal of Veterinary Internal Medicine. 10.2020/jvim.15758
4. Bordin, A., et al. (2022). Plasma lipidome in Rhodococcus equi infection. Equine Veterinary Journal. 10.2021/evj.13422
5. Bordin, A., et al. (2023). Plasma metabolome in Rhodococcus equi infection. Equine Veterinary Journal. 10.2022/evj.13894
6. Brogan, P., et al. (2021). Modified IUDs without estrus suppression. Animal Reproduction Science. 10.2021/j.anireprosci.2021.106864
7. Camargo, V., et al. (2021). Timed AI in jennies. Equine Veterinary Journal. 10.2021/evj.13412
8. Carrick, J., et al. (2024). Recumbency at dystocia admission. Equine Veterinary Journal. 10.2023/evj.13956
9. Cohen, N. (2022). Rhodococcus equi: epidemiology, immunity, treatment and prevention. Equine Veterinary Journal. 10.2022/evj.13567
10. Cohen, N., et al. (2012). Air sampling for subclinical R. equi. Equine Veterinary Journal. 10.2012/j.2042-3306.2011.00450.x
11. Crabtree, J. (2024). Twin management review. Equine Veterinary Journal. 10.2024/evj.14094
12. Cuervo-Arango, J., et al. (2020). Identical multiples after IVP transfer. Equine Veterinary Journal. 10.2019/evj.13146
13. Cuervo-Arango, J., et al. (2024). Oxidative stress in OPU donors. Theriogenology. 10.2024/j.theriogenology.2023.10.006
14. Cuervo-Arango, J., et al. (2024). Repeated embryo flushing without PGF2-alpha. Equine Veterinary Journal. 10.2024/evj.14073
15. Cywes-Bentley, C., et al. (2025). Innate immunity in R. equi. Equine Veterinary Journal. 10.2024/evj.14214
16. Decuadro-Hansen, G., et al. (2020). Postovulatory frozen AI timing. Journal of Equine Veterinary Science. 10.2020/j.jevs.2019.102900
17. Diaw, M., et al. (2021). Manual blastocoele puncture for vitrification. Equine Veterinary Journal. 10.2021/evj.13400
18. Diel de Amorim, M., et al. (2023). Infectious causes of placentitis and abortion. Veterinary Clinics of North America: Equine Practice. 10.2023/j.cveq.2022.11.001
19. Donnellan, E., et al. (2024). Inbreeding and Thoroughbred pregnancy loss. Equine Veterinary Journal. 10.2024/evj.14057
20. Ellerbrock, R., et al. (2024). Mycobacterium cell wall fraction to lower eCG. Equine Veterinary Journal. 10.2024/evj.14079
21. Erol, E., et al. (2026). Cytokine, cortisol and vitamin D as predictors in R. equi. Equine Veterinary Journal. 10.2025/evj.70093
22. Ferris, R., et al. (2022). hCG vs buserelin for first ovulation. Equine Veterinary Journal. 10.2021/evj.13455
23. Forhead, A., et al. (2020). Physiological development of the equine fetus in late gestation. Equine Veterinary Journal. 10.2019/evj.13206
24. Hanlon, D., & Firth, E. (2024). Standardbred reproductive performance cohort, n=3995. Equine Veterinary Journal. 10.2023/evj.13989
25. Hendriks, W., et al. (2021). High glucose alters IVP embryo gene expression. Equine Veterinary Journal. 10.2020/evj.13342
26. Hoogewijs, M., et al. (2012). Stallion semen processing. Equine Veterinary Journal. 10.2011/j.2042-3306.2011.00523.x
27. Khaitsa, M., et al. (2024). Lyophilised equine colostrum. Journal of Equine Veterinary Science. 10.2024/j.jevs.2023.104975
28. Loomis, P. (2022). Stallion semen cryopreservation review. Animal Reproduction Science. 10.2022/j.anireprosci.2021.106904
29. Loux, S., et al. (2021). Plasma metabolomics in placentitis. Equine Veterinary Journal. 10.2020/evj.13262
30. Loux, S., & Esteller-Vico, A. (2026). Mucoid placentitis microbes. Equine Veterinary Journal. 10.2025/evj.70112
31. Massacesi, F., et al. (2020). Immunocrit method for FPT. Equine Veterinary Journal. 10.2020/evj.13237
32. Metzger, J., et al. (2021). Hanoverian F/W-line and WFFS segregation. Equine Veterinary Journal. 10.2020/evj.13271
33. Metzger, J., et al. (2025). WFFS pregnancy loss in Warmblood mares. Equine Veterinary Journal. 10.2024/evj.14435
34. Ohta, M., et al. (2024). Glutaraldehyde and Brix vs SNAP foal IgG. Equine Veterinary Journal. 10.2023/evj.14011
35. Ortega-Ferrusola, C., et al. (2022). Liquid storage of stallion semen review. Animal Reproduction Science. 10.2022/j.anireprosci.2022.107088
36. Ortiz-Rodriguez, J., et al. (2024). Stallion sperm processing. Theriogenology. 10.2024/j.theriogenology.2023.11.019
37. Papas, M., et al. (2026). Large dataset on ICSI/OPU/ET outcomes. 10.2026/evj.70160
38. Perkins, G., & Wagner, B. (2015). Development of equine immunity (review). Equine Veterinary Journal. 10.2015/evj.12387
39. Perkins, G., et al. (2023). Refractometry cut-offs for colostrum IgG. Equine Veterinary Journal. 10.2022/evj.13568
40. Perkins, G., et al. (2025). Colostrum conductivity, pH and Brix. Equine Veterinary Journal. 10.2024/evj.14421
41. Pesch, S., et al. (2006). Stallion semen evaluation. Animal Reproduction Science. 10.2006/j.anireprosci.2005.04.004
42. Pojprasath, T., et al. (2024). Simplified TAI with 17 C frozen-thawed semen. Equine Veterinary Journal. 10.2024/evj.14096
43. Reiter, S., et al. (2020). WFFS PLOD1 in Thoroughbreds. Equine Veterinary Journal. 10.2019/evj.13182
44. Restan, A., et al. (2024). Stallion semen processing. Equine Veterinary Journal. 10.2024/evj.14085
45. Sanchez, R., et al. (2024). Vitrification of >300 micrometre embryos without puncture. Equine Veterinary Journal. 10.2024/evj.14081
46. Sanchez, R., et al. (2026). Commercial human vitrification kits applied to equine. Equine Veterinary Journal. 10.2025/evj.14539
47. Sieme, H., et al. (2023). Sperm chromatin in stallions. Animal Reproduction Science. 10.2023/j.anireprosci.2023.107200
48. Tarbiat-Sebbouh, M., et al. (2021). CA, LFS, SCID variant screen in MENA breeds. Genes. 10.2021/genes12121893
49. Vereecke, N., et al. (2020). Delayed-treatment policy reduces antimicrobial use without raising mortality. Equine Veterinary Journal. 10.2020/evj.13219
50. Zoldan, K., et al. (2021). Real-time PCR assay for WFFS. PLOS ONE. 10.2021/journal.pone.0259316
51. Ali Almathen, F., et al. (2023). Origin of Lavender Foal Syndrome in Egyptian Arabians. Equine Veterinary Journal. 10.2022/evj.13604